Documents

February 2014

• GOP Lawmakers: OIG Shows Weak Administration Oversight Of 340B Drug Discount Program
• GOP Lawmakers: OIG Shows Weak Administration Oversight Of 340B Drug Discount Program
• GOP Lawmakers: OIG Shows Weak Administration Oversight Of 340B Drug Discount Program
• GOP Lawmakers: OIG Shows Weak Administration Oversight Of 340B Drug Discount Program
• GOP Lawmakers: OIG Shows Weak Administration Oversight Of 340B Drug Discount Program
• GOP Lawmakers: OIG Shows Weak Administration Oversight Of 340B Drug Discount Program
• GOP Lawmakers: OIG Shows Weak Administration Oversight Of 340B Drug Discount Program
• GOP Lawmakers: OIG Shows Weak Administration Oversight Of 340B Drug Discount Program
• GOP Lawmakers: OIG Shows Weak Administration Oversight Of 340B Drug Discount Program
• Williams Formally Contests OSHA PSM Citations
• Health CO-OP Association Releases Oversight Testimony
• BARDA, Rempex Enter Agreement To Develop Drug Targeting Antibiotic-Resistant Infections
• CBO's Latest Budget Outlook
• Coalition Of Generics, Plans, Unions & Distributors Urge Congress To Fill REMS Loophole As SGR Offset
• GPhA-Sponsored Report Says FDA Labeling Rule Would Increase Generic Drug Spending By Billions
• CRS Issues GOP-Requested Analysis On Funding Risk Corridor Payments
• GAO Examines January 2013 Individual Market Base Premiums
• Safety Engineers Group Files Comment On Silica
• NIOSH Emphasizes Workplace Cancer Concern
• CMS Issues Draft 2015 Letter To Federal Exchange Insurers
• DOL Secretary Names 15 To Maritime Safety Panel
• Employers Urge Congress To Address ACA Full-Time Definition
• CDER Releases Guidance Agenda For 2014
• HHS Strengthens Patients’ Right To Access Lab Test Reports
• CMS Issues Additional Guidance On Under-65 Medicare Beneficiaries With High-Risk Pool Coverage